Xencor Inc
XNCR7.927USD
-0.053-0.66%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
563.90MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Xencor Inc Unternehmen
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly owned development candidates include Vudalimab, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, and Novartis XmAb undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of fbalropendekin alfa (XmAb306/RG6323), XmAb564, and XmAb662. Its other clinical-stage drug candidates consist of Obexelimab, AIMab7195 (XmAb7195), and Xpro1595. Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Unternehmensinformationen
BörsenkürzelXNCR
Name des UnternehmensXencor Inc
IPO-datumDec 03, 2013
CEODr. Bassil I. Dahiyat, Ph.D.
Anzahl der mitarbeiter250
WertpapierartOrdinary Share
GeschäftsjahresendeDec 03
Addresse465 N. Halstead St.
StadtPASADENA
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl91107
Telefon16263055900
Websitehttps://xencor.com/
BörsenkürzelXNCR
IPO-datumDec 03, 2013
CEODr. Bassil I. Dahiyat, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. John R. Desjarlais, Ph.D.
Dr. John R. Desjarlais, Ph.D.
Executive Vice President - Research, Chief Scientific Officer
Executive Vice President - Research, Chief Scientific Officer
212.96K
+10.45%
Ms. Celia E. Eckert
Ms. Celia E. Eckert
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
50.68K
+47.02%
Mr. Bart Jan Cornelissen
Mr. Bart Jan Cornelissen
Senior Vice President, Chief Financial Officer
Senior Vice President, Chief Financial Officer
33.17K
-10.16%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Independent Director
Independent Director
14.20K
+305.17%
Mr. Todd E. Simpson
Mr. Todd E. Simpson
Independent Director
Independent Director
13.69K
--
Mr. Richard J. (Rich) Ranieri
Mr. Richard J. (Rich) Ranieri
Independent Director
Independent Director
13.20K
+427.04%
Dr. Kevin C. Gorman, Ph.D.
Dr. Kevin C. Gorman, Ph.D.
Independent Director
Independent Director
--
--
Dr. Bassil I. Dahiyat, Ph.D.
Dr. Bassil I. Dahiyat, Ph.D.
President, Chief Executive Officer, Founder and Director
President, Chief Executive Officer, Founder and Director
--
--
Dr. A. Bruce Montgomery, M.D.
Dr. A. Bruce Montgomery, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Ellen Gwen Feigal, M.D.
Dr. Ellen Gwen Feigal, M.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. John R. Desjarlais, Ph.D.
Dr. John R. Desjarlais, Ph.D.
Executive Vice President - Research, Chief Scientific Officer
Executive Vice President - Research, Chief Scientific Officer
212.96K
+10.45%
Ms. Celia E. Eckert
Ms. Celia E. Eckert
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
50.68K
+47.02%
Mr. Bart Jan Cornelissen
Mr. Bart Jan Cornelissen
Senior Vice President, Chief Financial Officer
Senior Vice President, Chief Financial Officer
33.17K
-10.16%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Independent Director
Independent Director
14.20K
+305.17%
Mr. Todd E. Simpson
Mr. Todd E. Simpson
Independent Director
Independent Director
13.69K
--
Mr. Richard J. (Rich) Ranieri
Mr. Richard J. (Rich) Ranieri
Independent Director
Independent Director
13.20K
+427.04%
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Royalties
18.23M
55.70%
Milestone
14.50M
44.30%
Keine Daten
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Royalties
18.23M
55.70%
Milestone
14.50M
44.30%
Aktionärsstatistik
Aktualisiert: Sat, May 17
Aktualisiert: Sat, May 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
15.09%
PRIMECAP Management Company
13.71%
The Vanguard Group, Inc.
12.12%
EcoR1 Capital, LLC
8.63%
T. Rowe Price Associates, Inc.
5.38%
Other
45.06%
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
15.09%
PRIMECAP Management Company
13.71%
The Vanguard Group, Inc.
12.12%
EcoR1 Capital, LLC
8.63%
T. Rowe Price Associates, Inc.
5.38%
Other
45.06%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
59.58%
Investment Advisor/Hedge Fund
31.25%
Hedge Fund
15.77%
Research Firm
2.93%
Venture Capital
1.94%
Individual Investor
1.32%
Pension Fund
1.03%
Bank and Trust
0.36%
Sovereign Wealth Fund
0.25%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
437
81.46M
114.46%
-1.77M
2025Q1
459
80.70M
113.40%
-3.00M
2024Q4
454
76.54M
108.64%
-2.55M
2024Q3
455
73.66M
105.55%
+3.66M
2024Q2
436
65.64M
106.20%
-4.06M
2024Q1
431
66.91M
108.52%
-498.74K
2023Q4
420
65.39M
107.20%
-1.62M
2023Q3
417
65.14M
107.37%
-1.33M
2023Q2
422
64.91M
107.12%
-2.55M
2023Q1
418
65.89M
109.12%
+515.07K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
10.74M
15.09%
-230.83K
-2.10%
Mar 31, 2025
PRIMECAP Management Company
9.76M
13.71%
+776.58K
+8.64%
Mar 31, 2025
The Vanguard Group, Inc.
7.88M
11.08%
-118.90K
-1.49%
Mar 31, 2025
EcoR1 Capital, LLC
6.14M
8.63%
--
--
Mar 31, 2025
T. Rowe Price Associates, Inc.
3.83M
5.38%
-108.25K
-2.75%
Mar 31, 2025
State Street Global Advisors (US)
3.68M
5.18%
+482.80K
+15.08%
Mar 31, 2025
BVF Partners L.P.
2.74M
3.85%
+451.38K
+19.72%
Mar 31, 2025
TCG Crossover Management, LLC
2.45M
3.45%
--
--
Mar 31, 2025
RTW Investments L.P.
2.40M
3.38%
--
--
Mar 31, 2025
Dimensional Fund Advisors, L.P.
1.74M
2.44%
+235.86K
+15.71%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Genomics Immunology and Healthcare ETF
1.21%
Virtus LifeSci Biotech Clinical Trials ETF
0.75%
Invesco NASDAQ Future Gen 200 ETF
0.44%
Invesco S&P SmallCap Health Care ETF
0.4%
ALPS Medical Breakthroughs ETF
0.38%
SPDR S&P Biotech ETF
0.18%
Inspire Small/Mid Cap ESG ETF
0.14%
Direxion Daily S&P Biotech Bull 3X Shares
0.1%
SPDR SSGA US Small Cap Low Volatility Index ETF
0.08%
Invesco Nasdaq Biotechnology ETF
0.06%
Mehr Anzeigen
iShares Genomics Immunology and Healthcare ETF
Anteil1.21%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.75%
Invesco NASDAQ Future Gen 200 ETF
Anteil0.44%
Invesco S&P SmallCap Health Care ETF
Anteil0.4%
ALPS Medical Breakthroughs ETF
Anteil0.38%
SPDR S&P Biotech ETF
Anteil0.18%
Inspire Small/Mid Cap ESG ETF
Anteil0.14%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.1%
SPDR SSGA US Small Cap Low Volatility Index ETF
Anteil0.08%
Invesco Nasdaq Biotechnology ETF
Anteil0.06%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
